IQE plc
("IQE" or the "Company")
Directors' Dealings
IQE announces that on 31 March 2010, Phil Rasmussen, Group Finance Director of
IQE, purchased 60,000 ordinary shares in the Company at an average price of
16.5 pence per share. Following this transaction, Mr Rasmussen's total
beneficial interest in the Company is 60,000 ordinary shares representing
0.013% of the issued share capital.
In addition, IQE announces that Dr Drew Nelson, Chief Executive of IQE, as part
of the rearrangement of his personal pension and IQE shareholding, on 01
April sold 1,384,126 ordinary shares of IQE at 15.75 pence per share and his
personal SIPP has purchased 1,384,126 ordinary shares of IQE at 15.75 pence per
share, by means of a simultaneous purchase and sale transaction.
Following this transaction, Dr Nelson's sole beneficial interest in ordinary
shares of IQE, including those held within his SIPP, remains unchanged at
27,391,303 shares representing 6.168% of the issued share capital of the
Company, being 444,044,832.
Contacts:
IQE plc (+44 29 2083 9400)
Chris Meadows
Execution Noble & Company Limited (+ 44 20 7456 9191)
John Llewellyn-Lloyd
Sam Reynolds
[HUG#1400542]
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.